Autologous Bone Marrow Mononuclear Cells in Liver Cirrhosis
NCT ID: NCT00832247
Last Updated: 2009-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
15 participants
INTERVENTIONAL
2009-01-31
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients will be submitted to frequent clinical, laboratorial and image evaluation during a one-year follow-up. A second liver biopsy will be done in the 3rd month after infusion to check histological, cellular and molecular evolutive changes.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Autologous bone marrow mononuclear cells infusion
At least 100.000.000 autologous BMMC will be infused in a peripheral vein once suspended in albumine during 10 minutes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Liver cirrhosis
* Moderate liver disfunction
Exclusion Criteria
* Pregnancy
* Significant comorbidity
* Portal vein thrombosis
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)
UNKNOWN
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
OTHER_GOV
Financiadora de Estudos e Projetos
OTHER
Oswaldo Cruz Foundation
OTHER
University of Edinburgh
OTHER
Universidade Federal do Rio de Janeiro
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Federal UNiversity of Rio de Janeiro
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guilherme FM Rezende, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Universidade Federal do Rio de Janeiro
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitário Clementino Fraga Filho
Rio de Janeiro, Rio de Janeiro, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CELTHEP-02
Identifier Type: -
Identifier Source: org_study_id